Inge Thulin Elected to Merck Board of Directors
January 24 2018 - 07:00AM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced that Inge Thulin, chairman of the board,
president and chief executive officer of 3M, will join the
company’s board of directors effective March 1, 2018. Mr. Thulin
will stand for election with the company’s other directors in
connection with Merck’s Annual Meeting of Shareholders on May 22,
2018. With the addition of Mr. Thulin, the Merck board will include
14 members.
“We are pleased to add Mr. Thulin to the Merck board and look
forward to benefiting from his extensive experience as a global
leader of an innovative and science-based company,” said Kenneth C.
Frazier, chairman and chief executive officer, Merck.
Mr. Thulin is chairman of the board, president and chief
executive officer of 3M, a company that applies science in
collaborative ways to improve lives and create solutions to global
problems. 3M has also been widely recognized for its commitment to
sustainability and diversity. Mr. Thulin began his career with 3M
in Europe in 1979 and since then has assumed several key roles of
increasing responsibility, most recently serving as chief operating
officer prior to his current role.
Mr. Thulin earned degrees in economics and marketing from the
University of Gothenburg in Sweden. He is a National Committee on
U.S.-China Relations Honoree, has received the Peter G. Peterson
Business Statesmanship Award from the Committee for Economic
Development, the Lucia Trade Award from the Swedish-American
Chamber of Commerce and the Hendrickson Medal for Ethical
Leadership. Most recently, Mr. Thulin was honored by Junior
Achievement of The Upper Midwest, Inc. as a 2016 Business Hall of
Fame Laureate.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us on Twitter, Facebook,
YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180124005155/en/
MerckMedia:Tracy Ogden, 908-740-1747orClaire Gillespie,
267-305-0932orInvestors:Teri Loxam, 908-740-1986orAmy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024